Ascentage Pharma FY25 net loss widens 206.4% to RMB 1.24 billion

• Ascentage Pharma posted a net loss of RMB 1.24 billion for fiscal year 2025, widening 206.4%.
• Revenue fell 41.5% to RMB 574.1 million.
• Loss before tax widened to RMB 1.24 billion from RMB 395.3 million.
• Selling and distribution expenses climbed 80.4% to RMB 353.6 million, while R&D spending rose 20.1% to RMB 1.14 billion.
• Cash and bank balances increased to RMB 2.47 billion as of Dec. 31, 2025, and Ascentage Pharma said existing cash and cash equivalents should fund operating expenses and capital expenditure needs for at least the next 12 months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-049412), on April 29, 2026, and is solely responsible for the information contained therein.